---
aliases: [pembrolizumab, Keytruda QLEX]
---
#actor #product #pharma #oncology

**Keytruda** — [[Merck]]'s blockbuster cancer immunotherapy. #1 drug globally by revenue. 40+ indications. Patent cliff 2028. Subcutaneous formulation (QLEX) launched Oct 2025.

---

## Overview

| Metric | Value |
|--------|-------|
| Generic name | Pembrolizumab |
| Owner | [[Merck]] |
| Type | PD-1 inhibitor (immunotherapy) |
| 2024 revenue | **$29.5B** |
| 2026 peak est. | ~$32.7B |
| Patent expiry | **2028 (US)** |

**Scale:** ~40% of Merck's total revenue. #1 selling drug globally.

---

## Revenue history

| Year | Revenue | Growth |
|------|---------|--------|
| 2023 | $25.0B | — |
| 2024 | $29.5B | +18% |
| 2025 H1 | $15.2B | +7% |
| 2026E | $32.7B | Peak |

---

## Indications (40+)

| Cancer type | Share of sales |
|-------------|----------------|
| **Lung cancer** | ~27% (largest) |
| Melanoma | Major |
| Head & neck | Major |
| Bladder | Growing |
| Renal cell | Growing |
| Gastric/esophageal | Growing |

Also approved: Hodgkin lymphoma, cervical, endometrial, solid tumors with [[MSI]]-H.

---

## New formulation: QLEX (Oct 2025)

| Feature | IV Keytruda | Keytruda QLEX |
|---------|-------------|---------------|
| Administration | Infusion (30 min) | Subcutaneous (3-5 min) |
| Setting | Infusion center | Office visit |
| Pricing | — | Similar |

**Strategy:** Subcutaneous version extends patent protection, improves patient convenience.

---

## Patent cliff (2028)

| Factor | Detail |
|--------|--------|
| US expiry | 2028 |
| Biosimilar threat | High — large molecule, complex |
| Revenue at risk | ~$30B annually |
| Merck response | QLEX, combos, new indications, M&A |

**Merck M&A strategy:** Acquiring assets to offset cliff — [[Revolution Medicines]] talks ($32B) driven by Keytruda combo potential.

---

## Combination therapies

| Partner drug | Indication | Status |
|--------------|------------|--------|
| Padcev (Astellas) | Bladder cancer | Approved ([[EU]] Aug 2024) |
| Chemo | NSCLC, mesothelioma | Approved |
| **Daraxonrasib** | Pancreatic, NSCLC | Phase 3 (Revolution) |

**Revolution combo:** 86% ORR with daraxonrasib in PD-L1 high patients.

---

## IRA price negotiation

| Date | Event |
|------|-------|
| 2026 | Keytruda enters Medicare negotiation |
| 2028 | Negotiated price takes effect |

Adds pricing pressure on top of patent cliff.

---

*Created 2026-01-17*

---

## Related

- [[Merck]] — owner
- [[Revolution Medicines]] — combo partner (daraxonrasib)
- [[Opdivo]] — competitor (Bristol-Myers)
- [[Biopharma]] — sector
- [[Pfizer]] — peer with patent cliff challenges
